(Q28182762)

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

De novo design of the hydrophobic cores of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Optimal sequence selection in proteins of known structure by simulated evolution

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Design and structural analysis of alternative hydrophobic core packing arrangements in bacteriophage T4 lysozyme

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Automated design of the surface positions of protein helices

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Design, structure and stability of a hyperthermophilic protein variant

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Electrostatics significantly affect the stability of designed homeodomain variants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Computational stabilization of human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Long-acting growth hormones produced by conjugation with polyethylene glycol.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Pegylation: a novel process for modifying pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Chemistry for peptide and protein PEGylation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Mono-N-terminal poly(ethylene glycol)-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching".

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Development and in vitro characterization of human recombinant thyrotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

A rational design strategy for protein hormone superagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Rational design of potent antagonists to the human growth hormone receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Computational design of an integrin I domain stabilized in the open high affinity conformation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Reduced antibody response to streptavidin through site-directed mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Stability engineering of antibody single-chain Fv fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Antibody humanization using monovalent phage display

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Strategies for selection of antibodies by phage display

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

1 reference

7 January 2021

New protein engineering approaches to multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

1 reference

7 January 2021

Fc receptors and their interactions with immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Increasing the serum persistence of an IgG fragment by random mutagenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Computational protein design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Energy estimation in protein design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Review: protein design--where we were, where we are, where we're going.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Computational protein design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

Protein design automation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021

De novo protein design: fully automated sequence selection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902610-2

7 January 2021